John E Flanagan

US Patent:

6777536, Aug 17, 2004

Filed:

Feb 27, 1995

Appl. No.:

08/393462

Inventors:

John G. Flanagan - Newton MA
Hwai-Jong Cheng - Boston MA

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

C07K 1400

US Classification:

530350, 536 231, 536 235, 435 71, 435 691, 4352523, 4353201

Abstract:

The present invention relates to the discovery of a novel EPH receptor ligand, referred to hereinafter as âElf-1â, which protein has apparently broad involvement in the formation and maintenance of ordered spatial arrangements of differentiated tissues in vertebrates, and can be used to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.

US Patent:

6818903, Nov 16, 2004

Filed:

Sep 13, 2002

Appl. No.:

10/243535

Inventors:

Kevin T. Schomacker - Maynard MA
Thomas Meese - Brookline MA
Michael Ouradnik - Wayland MA
John Flanagan - Holbrook MA
Harry Gao - Stoneham MA

Assignee:

Medispectra, Inc. - Lexington MA

International Classification:

G01T 110

US Classification:

2504581, 2504612

Abstract:

The invention provides an apparatus and methods for determining whether spectral data obtained from a region of a tissue sample are affected by an artifact. Artifacts include, for example, lighting artifacts such as glare and shadow and obstruction artifacts, such as blood, a speculum, a smoke tube, or other obstruction. Additionally, the invention provides an apparatus and methods for obtaining redundant spectral data of a given region of a sample. A redundant set of spectral data is useful where one or more artifacts affect some but not all sets of the spectral data, such that the redundant set of data is unaffected by the artifact and is representative of the tissue. An embodiment of the invention comprises using representative spectral data in diagnosing a condition of a region of tissue.

US Patent:

6919313, Jul 19, 2005

Filed:

Apr 1, 2002

Appl. No.:

10/113794

Inventors:

John G. Flanagan - Newton MA, US
Qiang Lu - Brookline MA, US
Edna E. Sun - Brookline MA, US

Assignee:

President & Fellows of Harvard College - Cambridge MA

International Classification:

A61K038/17
C07K014/46

US Classification:

514 12, 530350, 514 2, 514 8

Abstract:

Transmembrane B ephrins and their Eph receptors signal hi-directionally. The presently claimed invention describes a cytoplasmic protein, designated PDZ-RGS3, which binds B ephrins through a PDZ domain, and has a regulator of heterotrimeric G protein signaling (RGS) domain. PDZ-RGS3 mediates signaling from the ephrin-B cytoplasmic tail. SDF-1, a chemokine with a G protein coupled receptor, or BDNF, act as chemoattractants for cerebellar granule cells, with SDF-1 action being selectively inhibited by soluble EphB receptor. The claimed invention reveals a pathway that links reverse signaling to cellular guidance, uncovers a novel mode of control for G proteins, and demonstrates a mechanism for selective regulation of responsiveness to neuronal guidance cues. Further, compositions and methods of use are provided for modulating cell migration as a function of chemokines and GPCR interaction, to aid in the treatment of disease states and medical conditions, including cancer and immune responses such as allergy and autoimmune responses. In one embodiment, a method of altering the sensitivity of a cell to a chemokine is provided using a PDZ-RGS3 protein.

US Patent:

7459696, Dec 2, 2008

Filed:

Apr 18, 2003

Appl. No.:

10/418973

Inventors:

Kevin T. Schomacker - Maynard MA, US
John A. Flanagan - Holbrook MA, US
Rolf B. Saager - Rochester NY, US
Alex Zelenchuk - Stoughton MA, US
Thomas M. Meese - Brookline MA, US

International Classification:

G01N 21/64

US Classification:

2504581

Abstract:

The invention provides methods for calibrating spectral data acquisition systems. These calibration methods produce spectral data sufficiently accurate for use in tissue classification algorithms. The invention improves the accuracy of spectral-based tissue classification schemes, in part, by properly accounting for spatial variations, instrument-to-instrument variations, and patient-to-patient variations in the acquisition of spectral data from tissue samples. Effects that are accounted for include, for example, stray light effects, electronic background effects, variation in light energy delivered to a tissue sample, spatial heterogeneities of the illumination source, chromatic aberrations of the scanning optics, variation in wavelength response of the collection optics, and efficiency of the collection optics.

US Patent:

20020156239, Oct 24, 2002

Filed:

Jul 31, 2001

Appl. No.:

09/921984

Inventors:

John Flanagan - Newton MA, US
Hwai-Jong Cheng - Boston MA, US

International Classification:

C07K014/705
C07K016/28
C07H021/04
C12P021/02
C12N005/06
C12P021/06

US Classification:

530/350000, 530/388220, 536/023500, 435/069100, 435/325000, 435/320100

Abstract:

The present invention relates to the discovery of a novel EPH receptor ligand, referred to hereinafter as “Elf-1”, which protein has apparently broad involvement in the formation and maintenance of ordered spatial arrangements of differentiated tissues in vertebrates, and can be used to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.

US Patent:

20040214156, Oct 28, 2004

Filed:

May 19, 2004

Appl. No.:

10/848735

Inventors:

Kevin Schomacker - Maynard MA, US
Thomas Meese - Brookline MA, US
Michael Ouradnik - Wayland MA, US
John Flanagan - Holbrook MA, US
Harry Gao - Stoneham MA, US

Assignee:

MediSpectra, Inc. - Lexington MA

International Classification:

C12Q001/00
A61B005/00

US Classification:

435/004000, 600/315000

Abstract:

The invention provides an apparatus and methods for determining whether spectral data obtained from a region of a tissue sample are affected by an artifact. Artifacts include, for example, lighting artifacts such as glare and shadow and obstruction artifacts, such as blood, a speculum, a smoke tube, or other obstruction. Additionally, the invention provides an apparatus and methods for obtaining redundant spectral data of a given region of a sample. A redundant set of spectral data is useful where one or more artifacts affect some but not all sets of the spectral data, such that the redundant set of data is unaffected by the artifact and is representative of the tissue. An embodiment of the invention comprises using representative spectral data in diagnosing a condition of a region of tissue.

US Patent:

20120231014, Sep 13, 2012

Filed:

Aug 18, 2010

Appl. No.:

13/391210

Inventors:

John G. Flanagan - Weston MA, US
Alan Peter Tenney - New York NY, US
Yingjie Shen - Brighton MA, US
Jerry Silver - Bay Village OH, US

Assignee:

CASE WESTERN RESERVE UNIVERSITY - Cleveland OH
PRESIDENT AND FELLOWS OF HARVARD COLLEGE - Cambridge MA

International Classification:

A61K 39/395
A61P 25/00
A61K 38/46
A61K 38/17
C12N 5/0793
C12N 5/071

US Classification:

4241581, 435375, 424 946, 514 177, 4241721

Abstract:

A method of promoting neural cell regeneration is carried out by contacting a neural cell with a compound that inhibits the binding of a chondroitin sulfate proteoglycan (CSPG) to a cellular (e.g., trans-membrane) PTPσ protein. The neural cell is associated with an injury or neurodegenerative condition.

US Patent:

20140045762, Feb 13, 2014

Filed:

Feb 17, 2012

Appl. No.:

13/985629

Inventors:

John G. Flanagan - Weston MA, US
Yingjie Shen - Brighton MA, US
Edith Yvonne Jones - Oxford, GB
Alexandru Radu Aricescu - Oxford, GB
Charlotte Hannah Bonn - Oxford, DE

Assignee:

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY FO OXFORD - Oxford
PRESIDENT AND FELLOWS OF HARVARD COLLEGE - Cambridge MA

International Classification:

A61K 31/727
A61K 38/17

US Classification:

514 177, 435375, 514 56

Abstract:

Disclosed herein are methods of inducing neuronal outgrowth of a neuron. The methods comprise contacting the neuron with an agent that binds receptor protein tyrosine phosphatase δ (RPTPδ), to thereby induce neuronal outgrowth of the neuron. The agent may induces clustering of RPTPδ and/or inhibit binding of chondroitin sulfate proteoglycan (CSPG) to RPTPδ. Examples of suitable agents are heparan sulfate proteoglycan, heparan sulfate, heparan sulfate oligosaccharides, or heparin oligosaccharides. Additional agents are also disclosed. The neuron can be a CNS neuron or peripheral neuron. Also disclosed herein are methods of treating neuronal injury in a subject comprising, administering to the subject an agent that binds RPTPδ. Administration may be to a site of neuronal injury, to thereby induce neuronal outgrowth at the site of neuronal injury.